3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
16
Rectal Neoplasms
4
Colonic Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Neoplasms
2
Biliary Tract Neoplasms
2
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Metastatic Gastric Adenocarcinoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastric Cancer Adenocarcinoma Metastatic
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Desmoid Tumors
1
Craniopharyngioma
1
Colorectal Cancer Metastatic
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced/Metastatic Solid Tumors
1
Advanced Solid Tumors
1
Adenomatous Polyposis Coli
1
Adenocarcinoma Of Esophagus
1
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Dihydropyrimidine Dehydrogenase Deficiency
×
trifluridine tipiracil drug combination
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled